TW200744599A - 5-HT1B antagonist composition for depression, anxiety and cognition - Google Patents
5-HT1B antagonist composition for depression, anxiety and cognitionInfo
- Publication number
- TW200744599A TW200744599A TW095131957A TW95131957A TW200744599A TW 200744599 A TW200744599 A TW 200744599A TW 095131957 A TW095131957 A TW 095131957A TW 95131957 A TW95131957 A TW 95131957A TW 200744599 A TW200744599 A TW 200744599A
- Authority
- TW
- Taiwan
- Prior art keywords
- cognition
- anxiety
- depression
- antagonist composition
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to pharmaceutical compositions comprising benzyl(idene)-lactam derivatives of formula I, wherein R1 is a group of the fromula G1 or G2 depicted below, and a pharmaceutically acceptable salt or optical isomer thereof and at least one active agent selected from (a)a selective serotonin re-uptake inhibitor (SSRI), (b)an alpha-2-delta (A2D) ligand or (c) a corticotropin releasing factor (CRF) antagonist and optionally a pharmaceutically acceptable carrier.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71292805P | 2005-08-31 | 2005-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200744599A true TW200744599A (en) | 2007-12-16 |
Family
ID=37591532
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW095131957A TW200744599A (en) | 2005-08-31 | 2006-08-30 | 5-HT1B antagonist composition for depression, anxiety and cognition |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP2007063278A (en) |
AR (1) | AR056480A1 (en) |
TW (1) | TW200744599A (en) |
WO (1) | WO2007026224A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
CN106061964B (en) * | 2014-01-20 | 2019-10-25 | 豪夫迈·罗氏有限公司 | Neurogenetic N- phenyl-lactam derivatives and its purposes in the treatment of neuropathic conditions can be stimulated |
WO2020183011A1 (en) | 2019-03-14 | 2020-09-17 | Institut Curie | Htr1d inhibitors and uses thereof in the treatment of cancer |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA001485B1 (en) * | 1996-03-29 | 2001-04-23 | Пфайзер Инк. | Benzyl(idene)-lactam derivatives, their preparation and their use as selective (ant)agonists of 5-ht1a and/or 5-ht1d |
UA56185C2 (en) * | 1996-09-30 | 2003-05-15 | Пфайзер Інк. | Aralkyl- and aralkylidene heterocyclic lactams and imids, a pharmaceutical composition and a treatment method |
ATE276249T1 (en) * | 1999-12-29 | 2004-10-15 | Pfizer Prod Inc | OPTICALLY ACTIVE 3-((2-PIPERAZINYL-PHENYL)METHYL)-1-(4-(TRIFLUORO METHYL)-PHENYL)-2-PYRROLIDINONE AS SELECTIVE 5-HT1D RECEPTOR ANTAGONISTS |
WO2006075226A1 (en) * | 2005-01-13 | 2006-07-20 | Pfizer Products Inc. | 11c-labeled benzyl-lactam compounds and their use as imaging agents |
EP1891041A1 (en) * | 2005-06-17 | 2008-02-27 | Pfizer Products Incorporated | METABOLITES OF 1- [-6- (1-ETHYL-l-HYDROXY-PROPYL) -PYRIDIN-3-YL]-3- [2- (4-METHYL-PIPERAZIN-I-YL) -BENZYL]-PYRR0LIDIN-2-0NE AS SERATONIN RECEPTOR ANTAGONISTS |
-
2006
- 2006-08-21 WO PCT/IB2006/002377 patent/WO2007026224A2/en active Application Filing
- 2006-08-30 AR ARP060103798A patent/AR056480A1/en unknown
- 2006-08-30 TW TW095131957A patent/TW200744599A/en unknown
- 2006-08-30 JP JP2006233563A patent/JP2007063278A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2007026224A2 (en) | 2007-03-08 |
WO2007026224A3 (en) | 2007-12-21 |
AR056480A1 (en) | 2007-10-10 |
JP2007063278A (en) | 2007-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200970585A1 (en) | BENZAMIDE DERIVATIVES AS AGONISTS OF EP RECEPTORS | |
WO2007148185A3 (en) | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors | |
DE602006011752D1 (en) | PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES SUITABLE AS ANTICOAGULATING AGENTS | |
EA200900135A1 (en) | DERIVATIVES OF PYRAZOL AS A CYTOCHROME P450 INHIBITORS | |
TW200719886A (en) | Dihydrobenzofuran derivatives and uses thereof | |
WO2006014665A3 (en) | Arylpyrrolidine derivatives as nk-1/ssri antagonists | |
SE0400284D0 (en) | Novel compounds | |
MX2009004910A (en) | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h -pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto. | |
WO2010068760A3 (en) | New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication | |
UY29246A1 (en) | NEW COMPOUNDS | |
TW200745029A (en) | Sulfonamide derivatives exhibiting PGD2 receptor antagonism | |
MY148634A (en) | Pyridazinone derivatives | |
EA200701257A1 (en) | PYRROPHORASOLES AS A STRONGLY-ACTING KINASE INHIBITORS | |
EA200800162A1 (en) | NEW PHARMACEUTICAL COMPOSITIONS WITH DELAYED DELAYS AND METHODS FOR THEIR PREPARATION | |
DK1663206T3 (en) | 1- (2,3-Dimethyl-phenyl) -ethyl-1,3-dihydro-imizadol-2-thione as a non-sedative alpha 2A agonist | |
CO5630034A2 (en) | PROCEDURE AND PHARMACEUTICAL COMPOSITIONS TO TREAT ATEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED AFFECTIONS | |
ATE406360T1 (en) | ANTAGONISTS OF OPIOID RECEPTORS | |
MX2009004746A (en) | 1,2,4-triazole derivatives as sigma receptor inhibitors. | |
MX2009005217A (en) | Nitrogen-containing heterocyclic compounds and methods of use thereof. | |
UY29169A1 (en) | DERIVATIVES OF 2-AMIDO-4 FENILTIAZOL, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS | |
WO2007073303A3 (en) | Novel benzimidazole derivatives as vanilloid receptor 1 (vrl) inhibitors | |
EA200900631A1 (en) | SUBSTITUTED PYRAZOLES AND TRIAZOLES AS KIBB INHIBITORS (KYNESIN-PROTEIN VERETEN) | |
MX2008002805A (en) | Carboxamide derivatives as muscarinic receptor antagonists. | |
UA97348C2 (en) | HETEROCYCLIC NF-kB INHIBITORS | |
WO2007017728A3 (en) | Novel heterocyclic compounds |